ESC 2024 - The EMPRESS-MI study was designed to evaluate whether treatment with empagliflozin acutely post-MI could reduce the risk of adverse cardiac remodeling in a high risk population. Jaclyn Carberry summarizes the study findings.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - The EMPRESS-MI study was designed to evaluate whether treatment with empagliflozin acutely post-MI could reduce the risk of adverse cardiac remodeling in a high risk population. Jaclyn Carberry summarizes the study findings.
This video was recorded during the ESC Congress 2024 in London, UK.
Jaclyn Carberry, MD is a Clinical Research Fellow at the Univeristy of Glasgow in Glasgow, UK.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of EMPRESS-MI
Release date: 18 September 2024
ESC 2024 - The EMPRESS-MI study was designed to evaluate whether treatment with empagliflozin acutely post-MI could reduce the risk of adverse cardiac remodeling in a high risk population. Jaclyn Carberry summarizes the study findings.
This video was recorded during the ESC Congress 2024 in London, UK.
Jaclyn Carberry, MD is a Clinical Research Fellow at the Univeristy of Glasgow in Glasgow, UK.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of EMPRESS-MI
Release date: 18 September 2024
Stay current with the best on medical education
